Critical care E Gyan May 18

25 Questions | Total Attempts: 85

SettingsSettingsSettings
Critical care E Gyan May 18 - Quiz

. Welcome to TE E-GYAN Test Here is an opportunity to test your Product knowledge and Strategy. You have 20 minutes to complete this test. Please enter your Name , Emp. Code ,HQ and Select your state. Then press "Start" to begin the test. You can only attend the test once and hence make sure you have uninterrupted internet connectivity. All the best Micro Leadership Academy


Questions and Answers
  • 1. 
    What are the reasons to prescribe Ferisome?
    • A. 

      High bioavailability & High absorption

    • B. 

      Consistent Rise in Hemoglobin

    • C. 

      Dosage convenience & better compliance

    • D. 

      Negligible side effects unlike conventional & IV iron

    • E. 

      All of the above

  • 2. 
    Which is false statement for Darbosis?
    • A. 

      Long term extended dosing of Darbosis maintained Hb concentrations

    • B. 

      Convenient dosage schedule: weekly, once in 2 weeks and Monthly

    • C. 

      Darbosis is a new generation erythropoietin stimulating agent

    • D. 

      There is no cold chain management for Darbosis

  • 3. 
    As per International Journal of Renovascular Disease, which statement is correct about Eposis?
    • A. 

      Maintains stable hemoglobin in more than 90% patients

    • B. 

      Reduces blood transfusion by 50%

    • C. 

      Both option 1 & 2 are correct

    • D. 

      None of the above

  • 4. 
    Which is a false statement about Microfer?
    • A. 

      Microfer is not manufactured in USFDA approved plant

    • B. 

      Microfer shows comparable efficacy as FCM

    • C. 

      Microfer offers significant hemoglobin rise (6.47 to 11.85 g/dL) within 4 weeks

    • D. 

      Microfer used for anemia in CKD

  • 5. 
    Which is false statement about immunosuppressants?
    • A. 

      Seegraf (Tacrolimus) is the firs-line immunosuppressive drug

    • B. 

      Mycophen(Mycophenolate mofetil) reduces the risk of graft loss by 20% and acute rejection by 30% than Azathioprine

    • C. 

      Seegraf (Tacrolimus) provides long term benefits of graft function & graft survival

    • D. 

      None of the above

  • 6. 
    Which of the following important dates are celebrated by CCDian in Quarter I ?
    • A. 

      International nurses day - 12th May

    • B. 

      Lupus Day- 10th May

    • C. 

      Doctor's Day - 1st July

    • D. 

      All of the above

  • 7. 
    Fill in the blanks. Balanced………….., Promising……………. Is positioning statement of ……….. Brand.
    • A. 

      Prophylaxis, Coverage, Bipacef

    • B. 

      Coverage, Prophylaxis, Bipacef

    • C. 

      Prophylaxis, Coverage, Teglin

    • D. 

      Coverage, Prophylaxis, Teglin

  • 8. 
    Which sets of brand does not come under 'Navratna Brand'?
    • A. 

      Micropenam, Hopstin, Ferisome

    • B. 

      Microtaz, Cefglobe S Forte, Darbosis

    • C. 

      Micromax, Dolo IV, Eposis

    • D. 

      Icufos, Teglin, Linosept

  • 9. 
    Icufos offers ………% clinical improvement in pulmonary exacerbations caused by MDR P.aeruginosa
    • A. 

      85%

    • B. 

      91%

    • C. 

      95%

    • D. 

      80%

  • 10. 
    Hopstin can be administered by inhalation in patients with Pneumonia/VAP
    • A. 

      True

    • B. 

      False

  • 11. 
    Cefglobe S Forte is preferred 1st line drug as the Antipseudomonal agent
    • A. 

      True

    • B. 

      Cant' Say

    • C. 

      False

  • 12. 
    Tigecycline combination therapy approach causes …… fold lower incidence of CDI in IAI
    • A. 

      4 Fold

    • B. 

      6 Fold

    • C. 

      8 Fold

    • D. 

      10 Fold

  • 13. 
    Bipacef is recommended by …………… as drug of choice for the management of CAP & SSTI
    • A. 

      USFDA

    • B. 

      BTS

    • C. 

      WSES

    • D. 

      All of the above

  • 14. 
    What is double-carbepenem strategy?
    • A. 

      It is salvage therapy for resistant MDR/XDR/PDR infections.

    • B. 

      Most oftenly used against carbepenem-resistant Klebsiella pneumoniae

    • C. 

      Synergistic bactericidal activity has shown by consuming one carbepenem against beta-lactamase enzyme

    • D. 

      All of the above

  • 15. 
    Which product is not coming under product incentive?
    • A. 

      Cefgobe S Forte

    • B. 

      Ferisome

    • C. 

      Micropenam

    • D. 

      Hopstin

  • 16. 
    How many KDDC campaign has to be done by each SBM this year?
    • A. 

      4

    • B. 

      6

    • C. 

      8

    • D. 

      10

  • 17. 
    How many anemia campaign has to be done by each SBM this year?
    • A. 

      4

    • B. 

      6

    • C. 

      8

    • D. 

      10

  • 18. 
    How many Sepsis campaign has to be done by each SBM this year?
    • A. 

      4

    • B. 

      6

    • C. 

      8

    • D. 

      10

  • 19. 
    What is our productivity commitment for Ferisome this yearin strips?
    • A. 

      500 PCPM

    • B. 

      1000 PCPM

    • C. 

      1500 PCPM

    • D. 

      2000 PCPM

  • 20. 
    What is our productivity commitment for Micropenam this year in vials?
    • A. 

      250 PCPM

    • B. 

      500 PCPM

    • C. 

      750 PCPM

    • D. 

      1000 PCPM

  • 21. 
    Which brand is above 10 Crs in CCD as per AWACS?
    • A. 

      Micropenamm

    • B. 

      Ferisome

    • C. 

      Eposis

    • D. 

      All of the above

  • 22. 
    What should be minimum sales contribution from Nephrology product to total HQ sales?
    • A. 

      20%

    • B. 

      30%

    • C. 

      40%

    • D. 

      50%

  • 23. 
    How many award Micro-CCD has received from ISCCM in last 4 years?
    • A. 

      1

    • B. 

      2

    • C. 

      3

    • D. 

      4

  • 24. 
    Which is the brand leader for Fosfomycin injection?
    • A. 

      Crifos

    • B. 

      Fonyl

    • C. 

      Fosfotas

    • D. 

      Icufos

  • 25. 
    Which is the brand leader in Liposomal iron market?
    • A. 

      Ferisome

    • B. 

      Nexiron LP

    • C. 

      Speedral

    • D. 

      Iforu

Back to Top Back to top